Forxiga/Farxiga is already growing fast after becoming the first SGLT2 inhibitor to get approved for treating heart failure with reduced ejection fraction (HFrEF), which helped sales grow more ...
The approval gives Boehringer and Lilly an opportunity to regain ascendency in the SGLT2 market after a prolonged period of sustained growth for AZ's Forxiga (dapagliflozin) – known as Farxiga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback